modified PENTOCLO (mPENTOCLO)

Phase 3Small molecule

modified PENTOCLO (mPENTOCLO) is one of 2 small molecule programs targeting Osteoradionecrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoradionecrosisActive, not recruiting

OsteoradionecrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Osteoradionecrosis

#DrugCompanyPhaseTrials

Hyperbaric Oxygen

IIntermountain Health Care, Inc.

Phase 3

1 2

modified PENTOCLO (mPENTOCLO)

SSunnybrook Health Sciences Centre

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Osteoradionecrosis

NCT06055257

Clinical

Trials by Indication[1]

Osteoradionecrosis1 trial

Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT06055257·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for modified PENTOCLO (mPENTOCLO). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — modified PENTOCLO (mPENTOCLO) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for modified PENTOCLO (mPENTOCLO). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunnybrook Health Sciences Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSunnybrook Health Sciences Centre

modified PENTOCLO (mPENTOCLO)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Osteoradionecrosis1 trial

References

Drug Info

Quick Facts

Related News